INDEPENDENT NEWS

Munchkin US FDA Process on hold

Published: Thu 16 May 2019 01:52 PM
SYNLAIT MILK LIMITED ANNOUNCEMENT NZX: SML
ASX: SM1
16 May 2019
MUNCHKIN U.S. FDA PROCESS ON HOLD
The U.S. Food and Drug Administration (FDA) registration process required to launch Munchkin’s Grass Fed™ infant formula in the U.S. has been put on hold.
Synlait (NZX: SML; ASX: SM1) has been informed that the clinical study has been put on hold to allow Munchkin to explore other options in the U.S.
“Munchkin has not terminated its supply agreement with Synlait. For other markets where Grass Fed™ is sold the relationship continues with business as usual,” says Synlait CEO, Leon Clement.
The development will not have a material impact on Synlait’s forecast infant formula volumes.
ENDS

Next in Business, Science, and Tech

SFO Commences Enquiries Into Allegations Of COVID-19 Wage Subsidy Fraud
By: Serious Fraud Office
Preliminary Environmental Data On New Zealand’s Air Quality Released Today
By: Statistics New Zealand
Food Prices Rise For Sixth Consecutive Month
By: Statistics New Zealand
Robust Balance Sheets Yield Faster Economic Recovery
By: The Reserve Bank of New Zealand
Transpower Releases Independent Report Into Events Of August 9
By: Transpower
Latest Lockdown Adds Further Fuel To Industrial Property Market
By: Bayleys
View as: DESKTOP | MOBILE © Scoop Media